CARA News and Press, Cara Therapeutics Inc. From 12/06/19

STAMFORD, Conn., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

Cara Therapeutics (NASDAQ: CARA ) released topline results from its Phase 2 trial evaluating Oral KORSUVA in chronic kidney disease (CKD) patients with pruritus on Tuesday (December 3), sending its share prices — surprisingly — deep into the red. In the press release, the com...

Major benchmarks suffered significant losses on Tuesday, as investors had to deal with a reversal of fortune in ongoing trade negotiations between the U.S. and China. Market participants had gotten used to the idea that the two nations might be able to come up with a phased-in agreement on some ...

STAMFORD, Conn., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today anno...

Shares of Cara Therapeutics (NASDAQ: CARA) had plunged 27.8% lower as of 10:54 a.m. EST on Tuesday. The big drop came after the drugmaker announced results from a phase 2 clinical study evaluating Oral Korsuva in treating chronic kidney disease (CKD) patients with moderate to severe prurit...

ASLAN Pharmaceuticals (NASDAQ: ASLN )  -50%  on pricing equity offering. More news on: ASLAN Pharmaceuticals Limited, CBL & Associates Properties, Inc, Aldeyra Therapeutics, Inc., Stocks on the move, Read more ...

A Phase 2 clinical trial evaluating Cara Therapeutics' (NASDAQ: CARA ) Korsuva (difelikefalin) (formerly CR845) for the treatment of pruritus (itchy skin) in patients with moderate-to-severe chronic kidney disease (CKD) met the primary endpoint . More news on: Cara Therapeutics, Inc., H...

– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) – –  Oral KORSUVA™ well-tolerated after 12 weeks of treatment –...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 133 weeks of public selections as part of this ongoing live forward-testing. ...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 132 weeks of public selections as part of this ongoing live forward-testing. In...